Financials · Insurance Agents, Brokers & Service · NYSE · CIK 1794783 · FYE Jun 30 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $0.73Day +4.65%Mkt cap $122MP/E (FY) 2.6×1Y −60.3%Off 52W high −73.8%Vol (1Y) 107.4%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,361 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Fair value (model)$0.73 |
| Implied upside+4.9% |
| Valuation confidenceLOW |
| Short interest0.9% of sh out |
| Days to cover1.4d |
| 13F net flow (QoQ)+1.31% |
| Top-10 13F concentration64.3% |
| Next report (est.)2026-08-04 |
Fair value, confidence and the reverse-DCF grade are the MATERIALIZED daily snapshot (the same columns the screener serves), not a live model run. Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)2.6× |
| Sales (TTM)$1.64B |
| Earnings (TTM)$91.9M |
| ROE14.2% |
| YTD−48.5% |
| 1Y−60.3% |
| 3Y−61.6% |
| 5Y−95.9% |
| Since incept. (ann.)−49.6% |
Total return through 2026-07-30 · series begins 2021-02-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)107.4% |
| Ann. volatility (3Y)93.1% |
| Sharpe (1Y)−0.39 |
| Sharpe (3Y)0.11 |
| Max drawdown (1Y)−78.0% |
| Max drawdown (3Y)−90.2% |
| Beta (3Y vs SPY)3.68 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 10.7M | $7M | 6.08% | +0.8% |
| ABRAMS BISON INVESTMENTS, LLC | 7.9M | $5M | 4.49% | +0.0% |
| Mariner, LLC | 6.5M | $4M | 3.68% | +2.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.0M | $4M | 3.40% | new |
| GEODE CAPITAL MANAGEMENT, LLC | 3.5M | $2M | 1.98% | +3.4% |
| STATE STREET CORP | 3.0M | $2M | 1.70% | +0.8% |
| CAPTRUST FINANCIAL ADVISORS | 2.3M | $1M | 1.30% | +9.9% |
| Occam Crest Management LP | 2.0M | $1M | 1.13% | −4.2% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-05 | $0.11 | +266.7% | $430.9M | +5.6% |
| 2025-12-31 | 2026-02-05 | $0.26 | −13.3% | $537.1M | +11.6% |
| 2025-09-30 | 2025-11-06 | −$0.26 | — | $328.8M | +12.5% |
| 2025-06-30 | 2025-08-21 | — | — | $345.1M | +12.3% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-04 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Service 52% · Pharmacy 48%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
| Net margin3.1% |
| ROIC8.1% |
| Debt / equity1.10× |
| Total debt / EBITDA4.33× |
| Sales growth 3Y26.0% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
